BASE10 today announced new board member to the Board of Directors.BASE10 is excited to welcome Mr. Mark Oldroyd to the Board of Directors. Mark brings to BASE10 over 26 years of healthcare industry experience. He is currently the Chief Business Officer at C2i Genomics, where he leads global collaborations for the company. Most of his career has been focused on strategic revenue development at seven startup organizations. In addition to his current role, Mr. Oldroyd previously held leadership roles in business development and commercial channels at Foundation Medicine and Tempus. His education includes a Juris Doctor with a specialty in health law and policy.
Mr. Mark Oldroyd: "I am grateful to the founders for the opportunity to join the team at BASE10 Genetics. It is exciting to be joining the company as it is poised to become a leader in bringing precision technologies to real world application in multiple disease areas. I look forward to meeting many others in the organization as I get started."